Budget impact analysis of neoadjuvant nivolumab for non-small cell lung cancer in the Chilean public healthcare system: An exploratory economic assessment
Early incorporation of N + CT optimizes healthcare expenditure by providing access to therapies that improve survival rates while reducing the need for costly treatments in advanced stages. This approach represents a dominant strategy.
Authors
- Daniela Paredes-Fernández (ORCID: https://orcid.org/0000-0001-9127-5824)
- Rony Lenz-Alcayaga (ORCID: https://orcid.org/0000-0002-6417-3029)
- Francisco Orlandi-Jorquera
Institutions
- Universidad Andrés Bello (CL)
- Universidad Andrés Bello (CL)
- Thorax Foundation (GR)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2025-03-02
- DOI
- https://doi.org/10.1007/s12094-025-03872-7
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00